How significant is this drug for the company

The drug Kresladi, developed by Rocket Pharmaceuticals, is a significant asset for the company due to several reasons:

1. Potential for First Approval: Kresladi represents Rocket's first potential FDA approval, marking a significant milestone for the company. It is the company's most advanced gene therapy candidate in the clinical pipeline.
2. Treatment for Unmet Medical Need: Kresladi is designed to treat severe leukocyte adhesion deficiency-I (LAD-I), a rare and life-threatening pediatric disease with no cure currently available. The approval of Kresladi would address a significant unmet medical need, providing a potential cure for patients with this devastating condition.
3. Commercial Potential: The successful development and approval of Kresladi would allow Rocket to commercialize its first product, which could have a substantial impact on the company's financials and market position.
4. Pipeline Development: The approval of Kresladi could serve as a catalyst for the development of other gene therapies in Rocket's pipeline. It demonstrates the company's ability to bring a product to market, potentially attracting more investment and partnerships.
5. Market Opportunity: The market for rare disease treatments is growing, and the approval of Kresladi could position Rocket as a leader in this space. The company's focus on genetic therapies for rare disorders aligns with the increasing demand for such treatments.

In summary, the approval of Kresladi would be a critical achievement for Rocket Pharmaceuticals, not only because it would represent the company's first FDA approval but also because it would address a significant unmet medical need and open up commercial opportunities for the company.